Evaluation of the effectiveness of Cyclotide complex herbal syrup in preventing COVID-19 virus in exposed individuals

ABSTRACT

ConditionCOVID-19 viral disease.
Coronavirus infection, unspecified;B34.2

InterventionIntervention 1 Intervention group Consumable product includes herbal syrup composed of cyclopeptide fraction with Ziziphus spina-cristi and Pimpinela anisum hydroalcoholic extract and orange peel. The dose of the product is 20 ml every 8 hours after eating, which is prepared by Herbi Pharmed Pharmaceutical Company. Intervention 2 Control group do not use any drugs for prevention and only follow health protocols to prevent infection.

Primary outcome:Polymerase chain reaction (PCR) analysis result. Timepoint At the beginning of the intervention and the day 14. Method of measurement Polymerase chain reaction (PCR) analysis.;Liver function test result. Timepoint At the beginning of the intervention and the day 14. Method of measurement Measurement of aspartate aminotransferase (AST) and Alanine transaminase (ALT) factors.;Fragment D-dimer test result. Timepoint At the beginning of the intervention and the day 14. Method of measurement Blood test - Fragment D-dimer measurement.;Measurement of serum iron. Timepoint At the beginning of the intervention and the day 14. Method of measurement Blood test - Total iron binding capacity factor (TIBC) measurement.;COVID-19 Antibodies. Timepoint At the beginning of the intervention and the day 14. Method of measurement Measurement of IgG COVID-19 and IgM COVID-19 factors.

CriteriaInclusion criteria People over the age of 18 who have had close contact with a person with COVID-19 in the last 4 days and signed an informed consent form (close contact is defined as those who live at home with an infected person or depending on their employment situation in Less than two meters away from the infected person.) And have no previous or current history of COVID-19.
Age between 18 and 70 years
No previous diagnosis of COVID-19 (if possible, test negative for IgG and IgM antibodies.)
Absence of symptoms such as fever, body aches, olfactory and taste disturbances, cough, shortness of breath, diarrhea in the last 1 month

Exclusion criteria Current incidence of COVID-19 is confirmed by PCR and clinical signs.
History of autoimmune disease
History of rheumatic disease
Pregnancy and lactation
Age under 18 years
People sensitive to any component of the product
People who can not follow up.
Any clinical reason that may prevent you from entering the study.
Do not take two doses of the drug